Rapamycin off-label: the longevity evidence

Key takeaways

• Rapamycin (sirolimus) is FDA-approved as Rapamune for organ-transplant rejection prophylaxis (initial US approval 1999) and, as a topical gel, for tuberous sclerosis facial angiofibromas (Hyftor, 2022). Longevity use is entirely off-label.
• In NIA Interventions Testing Program mouse trials, rapamycin extended lifespan by about 9 to 14 percent at the standard dose (Harrison 2009) and by about 23 percent in males and 26 percent in females at a threefold-higher dose (Miller 2014).
• The strongest human data are the Mannick rapalog immune-aging trials (2014, 2018); the PEARL trial (2025) is the first dedicated longevity pilot, and it missed its primary endpoint, visceral fat.
• Off-label longevity dosing is intermittent (PEARL tested 5 and 10 mg weekly). The aim is to inhibit mTORC1 while sparing mTORC2, but no long-duration human outcome trial validates that rationale.
• Sirolimus is a CYP3A4 and P-gp substrate, so azole antifungals, macrolides, grapefruit juice, and cyclosporine raise blood levels. Common off-label adverse effects are mouth ulcers, raised lipids, and dose-dependent immunosuppression.

Discovery and product history

Rapamycin (sirolimus) came out of a soil sample collected on Easter Island (Rapa Nui) during a 1964 expedition. Researchers isolated Streptomyces hygroscopicus from the sample, found it produced a compound with antifungal activity, and named that compound rapamycin after Rapa Nui . It was later characterized as a potent inhibitor of the mTOR pathway and developed as an immunosuppressant. The FDA approved sirolimus (Rapamune) in 1999 for prophylaxis of organ rejection in renal transplantation .

Sirolimus later gained a labeled indication for lymphangioleiomyomatosis (LAM) , and in 2022 the FDA approved a topical sirolimus gel (Hyftor) for facial angiofibromas of tuberous sclerosis complex in patients aged 6 and older . The longevity conversation that surrounds rapamycin in 2026 is entirely off-label.

mTOR mechanism, in plain language

Mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that exists in two complexes, mTORC1 and mTORC2, and integrates nutrient, energy, and growth-factor signals. mTORC1 drives protein synthesis, lipid biogenesis, and cell growth, and it suppresses autophagy. Chronically high mTORC1 signaling is one of the pathways implicated in aging biology in preclinical models.

Rapamycin binds intracellular FKBP12, and the rapamycin-FKBP12 complex inhibits mTORC1 with high specificity. mTORC2 is also inhibited, but only with prolonged exposure, and the metabolic adverse effects of sirolimus (insulin resistance, dyslipidemia) are partly attributed to that mTORC2 inhibition. Pulsatile or intermittent dosing has been proposed as a way to keep the mTORC1 effect while sparing mTORC2.

The ITP mouse-lifespan results

The NIA-funded Interventions Testing Program (ITP) tested rapamycin in genetically heterogeneous mice across three independent sites. Harrison and colleagues (2009) reported that rapamycin extended median and maximum lifespan when started at 600 days of age (the equivalent of late middle age in humans), an increase of about 14 percent for females and 9 percent for males based on age at 90 percent mortality . The effect was reproduced in later ITP cohorts; at a threefold-higher dose, median lifespan rose about 23 percent in males and 26 percent in females .

That makes rapamycin one of the most reproducible pharmacological lifespan-extension findings in mammals. Magnitude varies by dose and sex, from roughly 9 to 14 percent at the standard dose up to about 23 to 26 percent at higher doses . It is the strongest single argument for the off-label longevity case.

The translation caveat is real: mice are not humans. The ITP cohorts used encapsulated dietary rapamycin to control for first-pass metabolism, doses were much higher on a milligram-per-kilogram basis than typical human off-label use, and species-specific aging biology means the lifespan magnitude does not transfer directly.

The Mannick immune-aging trials

Mannick and colleagues at Novartis ran a series of trials using the rapamycin analog (rapalog) RAD001 (everolimus) in older adults to test whether mTOR inhibition could improve immune-aging endpoints. The first trial (2014) randomized adults aged 65 and over to low-dose everolimus (0.5 mg daily, 5 mg weekly, or 20 mg weekly) for 6 weeks before influenza vaccination and reported an improved antibody response in the low-dose arms, about 20 percent better than placebo .

A 2018 follow-up combined low-dose everolimus with a catalytic mTOR inhibitor (BEZ235, which blocks both TORC1 and TORC2) in 264 older adults and reported a significant reduction in self-reported respiratory infections over the year after dosing versus placebo . Those two trials are the strongest published human signal that intermittent low-dose mTOR inhibition can produce a clinically relevant outcome.

The follow-on did not hold up. A related oral TORC1 inhibitor (RTB101, from resTORbio) went into a phase 3 respiratory-illness trial, PROTECTOR-1, that missed its primary endpoint (odds ratio 1.07, p = 0.65) in 2019, and development in that indication stopped, per the company's own press release (industry-funded) . So the immune-aging story is a positive phase 2 signal that failed to reproduce in a larger phase 3.

Other caveats: the trials used rapalogs, not sirolimus itself; the endpoints were specific (vaccine antibody titers, self-reported infections) rather than mortality or major morbidity; and the populations were small to moderate.

PEARL: the dedicated longevity pilot

The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial was a 48-week double-blind randomized trial of intermittent oral rapamycin (5 mg or 10 mg weekly, or placebo) in healthy adults aged 50 to 85, registered as NCT04488601 . One-year results were published in the journal Aging in 2025, from a 2024 preprint peer-reviewed the following year .

PEARL missed its primary endpoint: neither dose significantly reduced visceral fat versus placebo (p = 0.94) . Among the secondary endpoints, women on 10 mg weekly showed a significant gain in lean tissue mass (p = 0.01) and a significant improvement in self-reported pain (p = 0.02) . Adverse and serious adverse events were similar across the three arms, with gastrointestinal symptoms more common on rapamycin .

PEARL is the first published controlled longevity-focused trial of rapamycin in healthy adults. It is small, short, and surrogate-endpoint, and its headline result was negative, so it is not evidence that weekly rapamycin extends life or healthspan. What it does show is that intermittent low-dose rapamycin can be given to healthy adults with a tolerability profile close to placebo .

Kraig: a small human feasibility and safety pilot

Kraig and colleagues (2018) ran a randomized trial of rapamycin (1 mg daily for 8 weeks, with some measures out to 16 weeks) in healthy adults aged 70 to 95 . It was a feasibility and safety study, not powered for outcomes. It tracked tolerability, metabolic labs, immune parameters, and physical and cognitive performance, and reported that low-dose rapamycin was generally tolerated in this cohort . Other small human studies have looked at rapamycin in skin aging, muscle, and senescence biomarkers, all small and surrogate.

PK, half-life, and the intermittent-dosing rationale

Sirolimus has a long terminal half-life (about 62 hours in stable transplant patients) and is metabolized mainly by CYP3A4 . Target whole-blood trough concentrations for the labeled uses run about 5 to 15 ng/mL (the LAM dosing range) . Off-label longevity dosing (5 to 10 mg weekly) aims for much lower exposure and leans on the long half-life to hold some mTORC1 inhibition on a once-weekly schedule.

The intermittent-dosing rationale is that continuous mTORC1 inhibition eventually inhibits mTORC2 (insulin resistance, dyslipidemia) and raises infection risk, while pulsatile dosing may keep the targeted mTORC1 effect with less of the off-target burden. That rationale rests on mouse data and the Mannick rapalog trials; no long-duration human trial has validated it at the outcome level.

Adverse events and monitoring (label and off-label)

• Mouth ulcers (aphthous stomatitis): the most commonly reported adverse event at off-label longevity doses; usually mild and resolves with dose-holding.
• Hyperlipidemia (raised total cholesterol, LDL, triglycerides): the most consistent metabolic effect at therapeutic immunosuppressive doses; a smaller signal at intermittent low doses.
• Glucose intolerance and insulin resistance: more pronounced with continuous high-dose use; intermittent low-dose data show a smaller effect.
• Immunosuppression: dose-dependent. Therapeutic dosing increases opportunistic infection risk; weekly low-dose has a smaller signal but is not zero.
• Wound-healing impairment: documented at therapeutic doses; pre-surgical interruption is standard practice in transplant patients .
• Pulmonary toxicity: rare but documented (interstitial pneumonitis); the labeled warning applies to all sirolimus users .
• Pregnancy: sirolimus can cause fetal harm, and the label recommends effective contraception during treatment and for 12 weeks after the last dose .

Monitoring under the labeled uses includes trough blood levels (in transplant), lipid panels, fasting glucose or HbA1c, complete blood count, a metabolic panel with renal function, and watching for opportunistic infection . Off-label longevity protocols vary widely: some prescribers do periodic lab monitoring at intermittent dosing, others do not.

Drug interactions

Sirolimus is a CYP3A4 and P-gp substrate. Strong CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, grapefruit juice, ritonavir-class antivirals) raise sirolimus levels; strong inducers (rifampin, phenytoin, carbamazepine, St. John's wort) lower them. Co-administration with cyclosporine raises sirolimus exposure substantially, and the labeled dosing for that combination differs from sirolimus monotherapy .

For longevity-clinic users, the practical interactions to watch are grapefruit juice (a common cause of elevated whole-blood levels), antifungals prescribed for incidental infections, and protease inhibitors. Anyone on several CYP3A4-active medications needs closer monitoring than the standard intermittent regimen assumes.

The off-label-prescriber landscape

Off-label rapamycin prescribing for longevity is legal but unregulated in the US. A cluster of internal-medicine physicians, geroscience-affiliated clinicians, and longevity clinics write rapamycin prescriptions, usually alongside lab monitoring. Doses vary widely (1 to 10 mg weekly is most common), and compounding pharmacies fill many of them. The monitoring rigor and follow-up vary a lot between prescribers.

Rapamycin is prescription-only, with no over-the-counter pathway. Buying bulk sirolimus from research-chemical channels carries the same identity, purity, and contamination risks as any unregulated pharmaceutical-grade compound, so the source-vetting that applies to other self-sourced compounds applies here too.

What the trials do not answer

• Whether intermittent low-dose rapamycin in healthy adults extends lifespan or healthspan in the hard-outcome sense.
• Whether the mouse lifespan magnitude transfers to humans at any dose schedule.
• Whether the Mannick rapalog immune-aging benefit translates to sirolimus at the doses used in longevity clinics, given the phase 3 RTB101 failure.
• Whether long-term (5 to 10 year) intermittent dosing produces accumulating tolerability or adverse-event signals.
• Whether different intermittent schedules (weekly vs every other week vs other) change outcomes.
• Whether genetic or biomarker stratification (mTOR-pathway variants, baseline insulin sensitivity, biological-age clocks) predicts responders from non-responders.

Editorial summary

Rapamycin has among the strongest preclinical lifespan-extension data of any small molecule. The human data in 2026 are limited: the Mannick immune-aging trials, one published longevity pilot (PEARL) that missed its primary endpoint, and small feasibility studies. Off-label prescribing moves faster than the trials, and the drug itself is a well-characterized immunosuppressant with a known adverse-event and monitoring profile .

The largest ongoing outcome test is not in people. The Dog Aging Project's TRIAD trial is testing whether once-weekly rapamycin extends lifespan and healthspan in healthy middle-aged companion dogs, and it has not reported lifespan results .

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 12 entries, primary canon (PubMed, PMC, DailyMed, ClinicalTrials.gov, and the Rapamune and Hyftor labels) plus one company press release acknowledged inline, last reviewed 2026-07-08.